Breaking Finance News

Wedbush disclosed Prothena Corp (NDAQ:PRTA), bumping down its price target to $55.00 earlier today

Reporting a potential upside of 0.21%, Wedbush dropped the price target of Prothena Corp (NDAQ:PRTA) to $55.00

On Friday September 29, 2017, BTIG Research released a statement on Prothena Corp (NDAQ:PRTA) dropped the target price from $80.00 to $77.00 that suggested an upside of 0.16%.

Having a price of $45.31, Prothena Corp (NDAQ:PRTA) traded -1.06% lower on the day. With the last close down 0.35% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.01% over the same period. PRTA has recorded a 50-day average of $62.65 and a two hundred day average of $57.71. Trade Volume was down over the average, with 171,437 shares of PRTA changing hands under the typical 227,002

Recent Performance Chart

Prothena Corp (NDAQ:PRTA)

Prothena Corp has with a one year low of $40.58 and a one year high of $70.00 and has a market capitalization of $0.

A total of 7 analysts have released a report on Prothena Corp. Four analysts rating the company a strong buy, three analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $73.86.

General Company Details For Prothena Corp (NDAQ:PRTA)

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.